Abstract
An unprecedented amount of research activity has produced a greater understanding of the pathophysiology of ALS. There are now several potential pathogenic mechanisms that provide avenues for drug development. The positive results in clinical trials evaluating riluzole, a glutamate antagonist, supports the excitotoxicity …

This publication has 0 references indexed in Scilit: